<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861793</url>
  </required_header>
  <id_info>
    <org_study_id>ALKS 4230-001</org_study_id>
    <nct_id>NCT03861793</nct_id>
  </id_info>
  <brief_title>A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)</brief_title>
  <official_title>A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will characterize the safety and tolerability and identify the recommended Phase 2&#xD;
      dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with&#xD;
      pembrolizumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate ALKS 4230 administered SC as lead-in monotherapy and in combination&#xD;
      with pembrolizumab in subjects with advanced solid tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs), and identify the RP2D of ALKS 4230 in Part A</measure>
    <time_frame>From time of initiation of therapy until 30 days after last dose of study drug, assessed up to 24 months</time_frame>
    <description>Includes AEs that are both serious and drug-related</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects experiencing AEs that are both serious and drug-related in Part B</measure>
    <time_frame>From time of initiation of therapy until 30 days after last dose of study drug, assessed up to 24 months</time_frame>
    <description>Includes AEs that are both serious and drug-related</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Activity of combination treatment with ALKS 4230 and pembrolizumab in each Part B tumor type.</measure>
    <time_frame>From time of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
    <description>Overall Response rate (ORR) will be based on investigator review of radiographic and photographic images</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with objective evidence of Complete Response (CR)/immune CR (iCR)</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
    <description>Overall response rate (ORR) will be based on investigator review of radiographic or photographic images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with objective evidence of Partial Response (PR)/immune PR (iPR)</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
    <description>ORR will be based on investigator review of radiographic or photographic images</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in subjects with CR/iCR</measure>
    <time_frame>Time from the first documentation of complete response, measured approximately every 6 weeks, to the first documentation of objective tumor progression or death due to any cause (estimated up to 24 months)</time_frame>
    <description>CR/iCR duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in subjects with PR/iPR</measure>
    <time_frame>Time from the first documentation of complete response, measured approximately every 6 weeks, to the first documentation of objective tumor progression or death due to any cause (estimated up to 24 months)</time_frame>
    <description>PR/iPR duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-progression for Part B</measure>
    <time_frame>Assessed up to 24 months</time_frame>
    <description>Time from first dose of SC ALKS 4230 to the time of progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival for Part B</measure>
    <time_frame>Assessed up to 24 months</time_frame>
    <description>Time from first dose of SC ALKS 4230 to the time of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of ALKS 4230 will be determined at various time points</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle (each cycle is 21 days), assessed up to 24 months</time_frame>
    <description>Concentration vs time and standard pharmacokinetic (PK) parameters will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum will be assayed for the presence of anti-ALKS 4230 antibodies</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle (each cycle is 21 days), assessed up to 24 months</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping of peripheral blood mononuclear cells will be performed by flow cytometry at various time points</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle (each cycle is 21 days), assessed up to 24 months</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of proinflammatory cytokines will be assessed using a multiplex method at various time points</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle (each cycle is 21 days), assessed up to 24 months</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ALKS 4230</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered via SC injection once every 7 days or once every 21 days at escalating doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALKS 4230 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALKS 4230 will be administered via SC injection once every 7 or 21 days at escalating doses or at the recommended phase 2 dose and schedule; pembrolizumab will be administered as an intravenous infusion given over 30 minutes; the dose level for pembrolizumab will be 200 mg per the approved label. In December 2020, an RP2D of 3 mg with an administration schedule of q7d was determined for SC ALKS 4230.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALKS 4230</intervention_name>
    <description>SC injection administered in the back of the arm or the abdomen</description>
    <arm_group_label>ALKS 4230</arm_group_label>
    <arm_group_label>ALKS 4230 + pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Administered as an intravenous (IV) infusion over 30 minutes</description>
    <arm_group_label>ALKS 4230 + pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For Phase I the subject has histological or cytological evidence of a solid tumor. For&#xD;
             Phase II the subject must have 1 of the specified adult solid tumor types defined in&#xD;
             the protocol&#xD;
&#xD;
          -  Subject must have at least one target lesion based on RECIST&#xD;
&#xD;
          -  Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score&#xD;
             of 0 or 1&#xD;
&#xD;
          -  Subjects must have adequate liver function&#xD;
&#xD;
          -  Subjects must have adequate kidney function&#xD;
&#xD;
          -  Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy,&#xD;
             other prior systemic anticancer therapy, radiotherapy or surgery&#xD;
&#xD;
          -  Subjects who have received radiation therapy must wait at least 4 weeks after their&#xD;
             last radiation treatment before enrollment into the study&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test within 7 days of&#xD;
             the start of treatment and on Day 1 before the first dose is administered&#xD;
&#xD;
          -  Subject will agree to follow contraceptive requirements defined in the protocol&#xD;
&#xD;
          -  Additional criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is currently pregnant, planning to become pregnant, or breastfeeding&#xD;
&#xD;
          -  Subjects with an active infection or with a fever ≥ 38.5°C within 3 days of the first&#xD;
             scheduled day of dosing for Cycle 1&#xD;
&#xD;
          -  Subjects with active or symptomatic central nervous system metastases are excluded.&#xD;
             Subjects with central nervous system metastases are eligible for the study if the&#xD;
             metastases have been treated by surgery and/or radiation therapy, the subject is off&#xD;
             corticosteroids for at least 2 weeks, and the subject is neurologically stable&#xD;
&#xD;
          -  Subjects with known hypersensitivity to any components of ALKS 4230 or to&#xD;
             pembrolizumab or any of its excipients&#xD;
&#xD;
          -  Subjects who require pharmacologic doses of systemic corticosteroids are excluded;&#xD;
             replacement doses, topical, ophthalmologic, and inhalational steroids are permitted&#xD;
&#xD;
          -  Subjects who developed autoimmune disorders while on prior immunotherapy, including&#xD;
             pneumonitis, nephritis, and/or neuropathy&#xD;
&#xD;
          -  Subjects with any other concurrent uncontrolled illness, including mental illness or&#xD;
             substance abuse, which may interfere with the ability of the subjects to cooperate and&#xD;
             participate in the study&#xD;
&#xD;
          -  The subject is known to be positive for human immunodeficiency virus (HIV), hepatitis&#xD;
             B or C, or active tuberculosis, or has a known history of tuberculosis&#xD;
&#xD;
          -  Additional criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alkermes Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Senior Director, Global Clinical Services</last_name>
    <phone>888-235-8008 (US Only)</phone>
    <email>clinicaltrials@alkermes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Senior Director, Global Clinical Services</last_name>
    <phone>1-571-599-2702 (Global)</phone>
    <email>clinicaltrials@alkermes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Sites</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>11259</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alkermes</keyword>
  <keyword>IL-2</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>Oncology</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>Cytokine</keyword>
  <keyword>ALKS 4230</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Keytruda</keyword>
  <keyword>PD-L1</keyword>
  <keyword>Solid tumors</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>nemvaleukin alfa</keyword>
  <keyword>ovarian</keyword>
  <keyword>Head and Neck</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Non small cell lung cancer</keyword>
  <keyword>lung cancer</keyword>
  <keyword>Gastric</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Gastroesophageal Cancer</keyword>
  <keyword>Gastroesophageal junction (GEJ) adenocarcinoma</keyword>
  <keyword>GEJ Cancer</keyword>
  <keyword>adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>At this time, IPD sharing has not been defined and/or decided if it will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

